tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
kepmectin pro (10+100)mg/ml ενεσιμο διαλυμα
vetag ltd, ΑΓ. ΣΤΕΦΑΝΟΣ, ΑΘΗΝΑ (0000008935) gr - ΚΛΟΡΣΟΥΛΌΝΗ; ΙΒΕΡΜΕΚΤΊΝΗ - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - (10+100)mg/ml - clorsulon 100,00 inj.sol (10+100)mg/ml; ivermectin 10,00 inj.sol (10+100)mg/ml - ivermectin, combinations - Βοοειδή - Χρόνοι αναμονής: Βοοειδή 66 Ημέρες Κρέας και εδώδιμοι ιστοί
dextrose/demo 35% w/v solution for intravenous infusion
the star medicines importers co. ltd (0000003109) 10 loukis akritas str, lemesos, 3030 - glucose - solution for intravenous infusion - 35% w/v - glucose (0000050997) 350g - glucose
hibicet cut.sol 15%+1,5% (w/v)
cana Α.e. ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΗΡΑΚΛΕΙΟΥ 446, 14122 ΗΡΑΚΛΕΙΟ ΑΤΤΙΚΗΣ 2815502 - cetrimonium bromide; chlorhexidine gluconate - cut.sol (ΔΕΡΜΑΤΙΚΟ ΔΙΑΛΥΜΑ) - 15%+1,5% (w/v) - cetrimonium bromide 150mg; chlorhexidine gluconate 15mg - chlorhexidine, combinations
adempas
bayer ag - riociguat - Υπέρταση, πνευμονική - Αντιϋπερτασικά για πνευμονική αρτηριακή υπέρταση - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Η αποτελεσματικότητα έχει αποδειχθεί σε ΠΑΥ πληθυσμού, συμπεριλαμβανομένων αιτιολογίες ιδιοπαθής ή κληρονομική ΠΑΥ ή ΠΑΥ σχετιζόμενη με νόσο του συνδετικού ιστού. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
fylepsia 2mg film coated tablets
elpen pharmaceutical co inc (0000009615) 95 marathonos ave, pikermi, attica, 19009 - perampanel - film coated tablets - 2mg - perampanel (0380917975) 2mg
fylepsia 12mg film coated tablets
elpen pharmaceutical co inc (0000009615) 95 marathonos ave, pikermi, attica, 19009 - perampanel - film coated tablets - 12mg - perampanel (0380917975) 12mg
fylepsia 6mg film coated tablets
elpen pharmaceutical co inc (0000009615) 95 marathonos ave, pikermi, attica, 19009 - perampanel - film coated tablets - 6mg - perampanel (0380917975) 6mg
fylepsia 4mg film coated tablets
elpen pharmaceutical co inc (0000009615) 95 marathonos ave, pikermi, attica, 19009 - perampanel - film coated tablets - 4mg - perampanel (0380917975) 4mg
fylepsia 10mg film coated tablets
elpen pharmaceutical co inc (0000009615) 95 marathonos ave, pikermi, attica, 19009 - perampanel - film coated tablets - 10mg - perampanel (0380917975) 10mg